Compare LTRN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRN | FGEN |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 35.6M |
| IPO Year | 2020 | 2014 |
| Metric | LTRN | FGEN |
|---|---|---|
| Price | $2.97 | $8.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $25.00 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 67.7K | 40.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | N/A | ★ $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $4.85 |
| 52 Week High | $6.12 | $21.94 |
| Indicator | LTRN | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | 47.05 |
| Support Level | $3.32 | $8.36 |
| Resistance Level | $3.72 | $9.19 |
| Average True Range (ATR) | 0.26 | 0.64 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 5.21 | 16.59 |
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.